IncobotulinumtoxinA (Xeomin): Background, Mechanism of Action, and Manufacturing

Authors

Z Paul Lorenc
Jeffrey M Kenkel
Steven Fagien
Haideh Hirmand
Mark S Nestor
Anthony P Sclafani, New York Medical CollegeFollow
Jonathan M Sykes
Heidi A Waldorf

Author Type(s)

Faculty

DOI

10.1177/1090820X12474633

Journal Title

Aesthetic Surgery Journal

First Page

18

Last Page

18

Document Type

Article

Publication Date

3-1-2013

Department

Otolaryngology

Abstract

IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.

Recommended Citation

Lorenc, Z., Kenkel, J., Fagien, S., Hirmand, H., Nestor, M., Sclafani, A., Sykes, J., & Waldorf, H. (2013). IncobotulinumtoxinA (Xeomin): Background, Mechanism of Action, and Manufacturing. Aesthetic Surgery Journal, 33 (1 Suppl), 18-18. https://doi.org/10.1177/1090820X12474633